nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—CYP2C9—Capecitabine—esophageal cancer	0.264	0.665	CbGbCtD
Cyclizine—CYP2C9—Cisplatin—esophageal cancer	0.133	0.335	CbGbCtD
Cyclizine—SULT1E1—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.039	0.089	CbGpPWpGaD
Cyclizine—SULT1E1—Estrogen metabolism—CYP1B1—esophageal cancer	0.0356	0.0812	CbGpPWpGaD
Cyclizine—SULT1E1—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.0315	0.0718	CbGpPWpGaD
Cyclizine—SULT1E1—bronchus—esophageal cancer	0.0272	0.26	CbGeAlD
Cyclizine—SULT1E1—digestive system—esophageal cancer	0.021	0.201	CbGeAlD
Cyclizine—SULT1E1—lung—esophageal cancer	0.0176	0.168	CbGeAlD
Cyclizine—SULT1E1—Phase II conjugation—GSTO1—esophageal cancer	0.0162	0.0369	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTT1—esophageal cancer	0.0125	0.0286	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—ADH7—esophageal cancer	0.0125	0.0285	CbGpPWpGaD
Cyclizine—SULT1E1—lymph node—esophageal cancer	0.012	0.115	CbGeAlD
Cyclizine—SULT1E1—Biological oxidations—ADH1B—esophageal cancer	0.011	0.025	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP26A1—esophageal cancer	0.0102	0.0232	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.01	0.0229	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTO1—esophageal cancer	0.00947	0.0216	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTO1—esophageal cancer	0.00934	0.0213	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—ALDH2—esophageal cancer	0.00772	0.0176	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTT1—esophageal cancer	0.00734	0.0167	CbGpPWpGaD
Cyclizine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00734	0.0167	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP2A6—esophageal cancer	0.00726	0.0166	CbGpPWpGaD
Cyclizine—CYP2C9—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00706	0.0161	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—PTGS1—esophageal cancer	0.00688	0.0157	CbGpPWpGaD
Cyclizine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00668	0.0152	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP1B1—esophageal cancer	0.00585	0.0133	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00577	0.0132	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP19A1—esophageal cancer	0.0055	0.0125	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00542	0.0124	CbGpPWpGaD
Cyclizine—HRH1—epithelium—esophageal cancer	0.00494	0.0472	CbGeAlD
Cyclizine—HRH1—smooth muscle tissue—esophageal cancer	0.00476	0.0454	CbGeAlD
Cyclizine—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.00437	0.00998	CbGpPWpGaD
Cyclizine—HRH1—trachea—esophageal cancer	0.00437	0.0417	CbGeAlD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00421	0.0096	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00402	0.00916	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00402	0.00916	CbGpPWpGaD
Cyclizine—CYP2C9—digestive system—esophageal cancer	0.00381	0.0364	CbGeAlD
Cyclizine—HRH1—digestive system—esophageal cancer	0.00376	0.0359	CbGeAlD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00376	0.00857	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00358	0.00817	CbGpPWpGaD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00339	0.00774	CbGpPWpGaD
Cyclizine—Bifonazole—CYP19A1—esophageal cancer	0.00324	0.201	CrCbGaD
Cyclizine—HRH1—lung—esophageal cancer	0.00314	0.03	CbGeAlD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.003	0.00685	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—SLC52A3—esophageal cancer	0.00295	0.00674	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—BLVRB—esophageal cancer	0.00295	0.00674	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00287	0.00656	CbGpPWpGaD
Cyclizine—Flunarizine—CYP2A6—esophageal cancer	0.00274	0.169	CrCbGaD
Cyclizine—Hepatitis cholestatic—Capecitabine—esophageal cancer	0.00262	0.0603	CcSEcCtD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00255	0.00582	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00254	0.00579	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00252	0.00574	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—SLC10A2—esophageal cancer	0.00251	0.00573	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CA1—esophageal cancer	0.00251	0.00573	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CA2—esophageal cancer	0.0023	0.00524	CbGpPWpGaD
Cyclizine—Altered state of consciousness—Capecitabine—esophageal cancer	0.00228	0.0526	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00222	0.00507	CbGpPWpGaD
Cyclizine—Cinnarizine—CYP2A6—esophageal cancer	0.00217	0.134	CrCbGaD
Cyclizine—HRH1—lymph node—esophageal cancer	0.00215	0.0205	CbGeAlD
Cyclizine—SULT1E1—Metabolism—PLCE1—esophageal cancer	0.00214	0.00487	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ADH7—esophageal cancer	0.00214	0.00487	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00207	0.00472	CbGpPWpGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00199	0.00455	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00199	0.00455	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0019	0.00433	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ADH1B—esophageal cancer	0.00187	0.00427	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00182	0.00415	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00179	0.00409	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—TYMP—esophageal cancer	0.00179	0.00408	CbGpPWpGaD
Cyclizine—Reboxetine—ABCB1—esophageal cancer	0.00178	0.11	CrCbGaD
Cyclizine—SULT1E1—Metabolism—CYP26A1—esophageal cancer	0.00174	0.00397	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ALOX15—esophageal cancer	0.0017	0.00387	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00169	0.00387	CbGpPWpGaD
Cyclizine—Clozapine—CYP1B1—esophageal cancer	0.00163	0.101	CrCbGaD
Cyclizine—SULT1E1—Metabolism—GSTO1—esophageal cancer	0.00162	0.00369	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—TPI1—esophageal cancer	0.00162	0.00369	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00157	0.00357	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ALDOB—esophageal cancer	0.00155	0.00354	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GAPDH—esophageal cancer	0.00149	0.00341	CbGpPWpGaD
Cyclizine—Pain—Carboplatin—esophageal cancer	0.00149	0.0343	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CRABP1—esophageal cancer	0.00148	0.00338	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00147	0.00336	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00146	0.00334	CbGpPWpGaD
Cyclizine—Blister—Capecitabine—esophageal cancer	0.00146	0.0337	CcSEcCtD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00144	0.0033	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—GNG7—esophageal cancer	0.00141	0.00322	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GNG7—esophageal cancer	0.00141	0.00321	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0014	0.00319	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00138	0.00314	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00136	0.0031	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.00135	0.00307	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ALDH2—esophageal cancer	0.00132	0.00301	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00127	0.00289	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.00126	0.00288	CbGpPWpGaD
Cyclizine—Clozapine—CYP2A6—esophageal cancer	0.00126	0.0776	CrCbGaD
Cyclizine—SULT1E1—Metabolism—GSTT1—esophageal cancer	0.00126	0.00286	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP2A6—esophageal cancer	0.00124	0.00283	CbGpPWpGaD
Cyclizine—Diphenhydramine—PTGS1—esophageal cancer	0.00119	0.0737	CrCbGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00119	0.00271	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.00118	0.00269	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ENO1—esophageal cancer	0.00118	0.00268	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS1—esophageal cancer	0.00118	0.00268	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PSME2—esophageal cancer	0.00116	0.00264	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PSME1—esophageal cancer	0.00116	0.00264	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—ANXA1—esophageal cancer	0.00115	0.00264	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00112	0.00255	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.0011	0.00251	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—GHRL—esophageal cancer	0.00109	0.0025	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00108	0.00247	CbGpPWpGaD
Cyclizine—Injection site reaction—Capecitabine—esophageal cancer	0.00105	0.0242	CcSEcCtD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.00103	0.00236	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.00102	0.00233	CbGpPWpGaD
Cyclizine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00102	0.0235	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—EP300—esophageal cancer	0.00101	0.00231	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.00101	0.0023	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP1B1—esophageal cancer	0.001	0.00228	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.000979	0.00223	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP19A1—esophageal cancer	0.00094	0.00215	CbGpPWpGaD
Cyclizine—Apnoea—Methotrexate—esophageal cancer	0.000925	0.0213	CcSEcCtD
Cyclizine—Speech disorder—Methotrexate—esophageal cancer	0.000912	0.021	CcSEcCtD
Cyclizine—Bepridil—ABCB1—esophageal cancer	0.000886	0.0548	CrCbGaD
Cyclizine—Thrombophlebitis—Capecitabine—esophageal cancer	0.000883	0.0204	CcSEcCtD
Cyclizine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000875	0.0202	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—HMOX1—esophageal cancer	0.000858	0.00196	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000832	0.0019	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ABCB1—esophageal cancer	0.000824	0.00188	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000823	0.00188	CbGpPWpGaD
Cyclizine—Fentanyl—ABCB1—esophageal cancer	0.000815	0.0504	CrCbGaD
Cyclizine—Dermatitis bullous—Capecitabine—esophageal cancer	0.0008	0.0185	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000791	0.00181	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000782	0.00178	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000765	0.00175	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000764	0.00174	CbGpPWpGaD
Cyclizine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000757	0.0175	CcSEcCtD
Cyclizine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000756	0.0174	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—PIK3CA—esophageal cancer	0.00075	0.00171	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000744	0.0017	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000742	0.00169	CbGpPWpGaD
Cyclizine—Urinary retention—Capecitabine—esophageal cancer	0.000727	0.0168	CcSEcCtD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000725	0.00165	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000717	0.00164	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—GNG7—esophageal cancer	0.000711	0.00162	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000705	0.0163	CcSEcCtD
Cyclizine—Eye disorder—Cisplatin—esophageal cancer	0.000671	0.0155	CcSEcCtD
Cyclizine—Thrombophlebitis—Methotrexate—esophageal cancer	0.000658	0.0152	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000651	0.00149	CbGpPWpGaD
Cyclizine—Bronchospasm—Capecitabine—esophageal cancer	0.00065	0.015	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000631	0.00144	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CXCL2—esophageal cancer	0.000626	0.00143	CbGpPWpGaD
Cyclizine—Erythema—Cisplatin—esophageal cancer	0.000625	0.0144	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000622	0.00142	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000608	0.00139	CbGpPWpGaD
Cyclizine—Muscle spasms—Cisplatin—esophageal cancer	0.000601	0.0139	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—GDI2—esophageal cancer	0.000597	0.00136	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000593	0.00135	CbGpPWpGaD
Cyclizine—Vision blurred—Cisplatin—esophageal cancer	0.000589	0.0136	CcSEcCtD
Cyclizine—Tremor—Cisplatin—esophageal cancer	0.000585	0.0135	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000585	0.00133	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—ANXA1—esophageal cancer	0.000582	0.00133	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—SST—esophageal cancer	0.000567	0.00129	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000557	0.0129	CcSEcCtD
Cyclizine—HRH1—GPCR ligand binding—GHRL—esophageal cancer	0.000552	0.00126	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CREBBP—esophageal cancer	0.00055	0.00126	CbGpPWpGaD
Cyclizine—Agranulocytosis—Capecitabine—esophageal cancer	0.00055	0.0127	CcSEcCtD
Cyclizine—Convulsion—Cisplatin—esophageal cancer	0.000541	0.0125	CcSEcCtD
Cyclizine—Hepatitis—Capecitabine—esophageal cancer	0.000529	0.0122	CcSEcCtD
Cyclizine—Connective tissue disorder—Capecitabine—esophageal cancer	0.00052	0.012	CcSEcCtD
Cyclizine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00051	0.0118	CcSEcCtD
Cyclizine—Nervous system disorder—Cisplatin—esophageal cancer	0.0005	0.0115	CcSEcCtD
Cyclizine—Tachycardia—Cisplatin—esophageal cancer	0.000498	0.0115	CcSEcCtD
Cyclizine—Skin disorder—Cisplatin—esophageal cancer	0.000495	0.0114	CcSEcCtD
Cyclizine—Eye disorder—Capecitabine—esophageal cancer	0.000494	0.0114	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—NOS3—esophageal cancer	0.000493	0.00112	CbGpPWpGaD
Cyclizine—Hypotension—Cisplatin—esophageal cancer	0.000476	0.011	CcSEcCtD
Cyclizine—Chills—Capecitabine—esophageal cancer	0.000475	0.0109	CcSEcCtD
Cyclizine—Clozapine—ABCB1—esophageal cancer	0.000467	0.0289	CrCbGaD
Cyclizine—Mental disorder—Capecitabine—esophageal cancer	0.000463	0.0107	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000462	0.00105	CbGpPWpGaD
Cyclizine—Erythema—Capecitabine—esophageal cancer	0.00046	0.0106	CcSEcCtD
Cyclizine—Paraesthesia—Cisplatin—esophageal cancer	0.000458	0.0106	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PTGS2—esophageal cancer	0.000451	0.00103	CbGpPWpGaD
Cyclizine—Muscle spasms—Capecitabine—esophageal cancer	0.000443	0.0102	CcSEcCtD
Cyclizine—Drowsiness—Methotrexate—esophageal cancer	0.000439	0.0101	CcSEcCtD
Cyclizine—Pain—Cisplatin—esophageal cancer	0.000436	0.0101	CcSEcCtD
Cyclizine—Vision blurred—Capecitabine—esophageal cancer	0.000434	0.01	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—KMT2D—esophageal cancer	0.000431	0.000984	CbGpPWpGaD
Cyclizine—Tremor—Capecitabine—esophageal cancer	0.000431	0.00995	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000422	0.000964	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKAP13—esophageal cancer	0.000419	0.000957	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000415	0.00957	CcSEcCtD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000411	0.000937	CbGpPWpGaD
Cyclizine—Agranulocytosis—Methotrexate—esophageal cancer	0.000409	0.00944	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—GNG7—esophageal cancer	0.000402	0.000917	CbGpPWpGaD
Cyclizine—Hypertension—Capecitabine—esophageal cancer	0.000398	0.00917	CcSEcCtD
Cyclizine—Hepatitis—Methotrexate—esophageal cancer	0.000394	0.00908	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000385	0.000877	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PDE4D—esophageal cancer	0.000384	0.000875	CbGpPWpGaD
Cyclizine—Hypersensitivity—Cisplatin—esophageal cancer	0.000376	0.00866	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—EP300—esophageal cancer	0.000375	0.000855	CbGpPWpGaD
Cyclizine—Nervous system disorder—Capecitabine—esophageal cancer	0.000369	0.0085	CcSEcCtD
Cyclizine—Eye disorder—Methotrexate—esophageal cancer	0.000368	0.00849	CcSEcCtD
Cyclizine—Tachycardia—Capecitabine—esophageal cancer	0.000367	0.00846	CcSEcCtD
Cyclizine—Asthenia—Cisplatin—esophageal cancer	0.000366	0.00844	CcSEcCtD
Cyclizine—Skin disorder—Capecitabine—esophageal cancer	0.000365	0.00842	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—GNG7—esophageal cancer	0.000365	0.000833	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000358	0.000818	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000354	0.000808	CbGpPWpGaD
Cyclizine—Chills—Methotrexate—esophageal cancer	0.000353	0.00815	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—WWOX—esophageal cancer	0.000352	0.000803	CbGpPWpGaD
Cyclizine—Hypotension—Capecitabine—esophageal cancer	0.000351	0.0081	CcSEcCtD
Cyclizine—Mental disorder—Methotrexate—esophageal cancer	0.000345	0.00796	CcSEcCtD
Cyclizine—Erythema—Methotrexate—esophageal cancer	0.000343	0.00791	CcSEcCtD
Cyclizine—Insomnia—Capecitabine—esophageal cancer	0.00034	0.00784	CcSEcCtD
Cyclizine—Paraesthesia—Capecitabine—esophageal cancer	0.000337	0.00778	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—FKBP1A—esophageal cancer	0.000335	0.000763	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000329	0.000751	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—WIF1—esophageal cancer	0.000327	0.000746	CbGpPWpGaD
Cyclizine—Vision blurred—Methotrexate—esophageal cancer	0.000323	0.00745	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—CXCL2—esophageal cancer	0.000321	0.000734	CbGpPWpGaD
Cyclizine—Constipation—Capecitabine—esophageal cancer	0.000321	0.00741	CcSEcCtD
Cyclizine—Pain—Capecitabine—esophageal cancer	0.000321	0.00741	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—SST—esophageal cancer	0.00032	0.000731	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000319	0.000727	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000319	0.000727	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—GHRL—esophageal cancer	0.000312	0.000712	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000302	0.000689	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ANXA1—esophageal cancer	0.000299	0.000682	CbGpPWpGaD
Cyclizine—Urticaria—Capecitabine—esophageal cancer	0.000299	0.00689	CcSEcCtD
Cyclizine—Convulsion—Methotrexate—esophageal cancer	0.000297	0.00685	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—SST—esophageal cancer	0.000291	0.000663	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000286	0.000653	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000285	0.00065	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—GHRL—esophageal cancer	0.000283	0.000647	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PFN1—esophageal cancer	0.000282	0.000644	CbGpPWpGaD
Cyclizine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00028	0.00645	CcSEcCtD
Cyclizine—HRH1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000278	0.000634	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PIK3CA—esophageal cancer	0.000277	0.000633	CbGpPWpGaD
Cyclizine—Hypersensitivity—Capecitabine—esophageal cancer	0.000277	0.00639	CcSEcCtD
Cyclizine—Nervous system disorder—Methotrexate—esophageal cancer	0.000274	0.00633	CcSEcCtD
Cyclizine—Skin disorder—Methotrexate—esophageal cancer	0.000272	0.00627	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—CA1—esophageal cancer	0.000271	0.000618	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000271	0.000618	CbGpPWpGaD
Cyclizine—Asthenia—Capecitabine—esophageal cancer	0.00027	0.00622	CcSEcCtD
Cyclizine—Pruritus—Capecitabine—esophageal cancer	0.000266	0.00613	CcSEcCtD
Cyclizine—Hypotension—Methotrexate—esophageal cancer	0.000261	0.00603	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—ELMO1—esophageal cancer	0.000254	0.000579	CbGpPWpGaD
Cyclizine—Insomnia—Methotrexate—esophageal cancer	0.000253	0.00584	CcSEcCtD
Cyclizine—Paraesthesia—Methotrexate—esophageal cancer	0.000251	0.00579	CcSEcCtD
Cyclizine—Somnolence—Methotrexate—esophageal cancer	0.000249	0.00574	CcSEcCtD
Cyclizine—Dizziness—Capecitabine—esophageal cancer	0.000249	0.00573	CcSEcCtD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000248	0.000567	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKAP13—esophageal cancer	0.000248	0.000565	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CA2—esophageal cancer	0.000248	0.000565	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000242	0.000552	CbGpPWpGaD
Cyclizine—Pain—Methotrexate—esophageal cancer	0.000239	0.00552	CcSEcCtD
Cyclizine—Headache—Capecitabine—esophageal cancer	0.000235	0.00543	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.00023	0.000526	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ADH7—esophageal cancer	0.00023	0.000526	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000229	0.000522	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000228	0.000519	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDE4D—esophageal cancer	0.000227	0.000517	CbGpPWpGaD
Cyclizine—Urticaria—Methotrexate—esophageal cancer	0.000222	0.00513	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—GNG7—esophageal cancer	0.000216	0.000492	CbGpPWpGaD
Cyclizine—Hypersensitivity—Methotrexate—esophageal cancer	0.000206	0.00475	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—XIAP—esophageal cancer	0.000202	0.000461	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000202	0.000461	CbGpPWpGaD
Cyclizine—Asthenia—Methotrexate—esophageal cancer	0.000201	0.00463	CcSEcCtD
Cyclizine—Pruritus—Methotrexate—esophageal cancer	0.000198	0.00456	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000193	0.00044	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNA1—esophageal cancer	0.000191	0.000436	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL2—esophageal cancer	0.00019	0.000433	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000188	0.000428	CbGpPWpGaD
Cyclizine—Dizziness—Methotrexate—esophageal cancer	0.000185	0.00427	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000183	0.000417	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PSME2—esophageal cancer	0.000177	0.000405	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PSME1—esophageal cancer	0.000177	0.000405	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ANXA1—esophageal cancer	0.000177	0.000403	CbGpPWpGaD
Cyclizine—Headache—Methotrexate—esophageal cancer	0.000175	0.00404	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000175	0.000398	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000175	0.000398	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SST—esophageal cancer	0.000172	0.000392	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH3—esophageal cancer	0.000167	0.000382	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GHRL—esophageal cancer	0.000167	0.000382	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000167	0.000382	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FBXW7—esophageal cancer	0.000165	0.000376	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.000161	0.000368	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.00016	0.000364	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GNG7—esophageal cancer	0.000152	0.000346	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH2—esophageal cancer	0.00015	0.000343	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDH2—esophageal cancer	0.000142	0.000325	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTT1—esophageal cancer	0.000135	0.000309	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	0.000134	0.000305	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000133	0.000304	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	0.000133	0.000304	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS1—esophageal cancer	0.000127	0.000289	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ENO1—esophageal cancer	0.000127	0.000289	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SMAD4—esophageal cancer	0.000126	0.000288	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PSME1—esophageal cancer	0.000125	0.000285	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PSME2—esophageal cancer	0.000125	0.000285	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000109	0.000249	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	0.000108	0.000246	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	0.000103	0.000235	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	0.000101	0.000231	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KDR—esophageal cancer	9.86e-05	0.000225	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	9.29e-05	0.000212	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMOX1—esophageal cancer	9.25e-05	0.000211	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	9.08e-05	0.000207	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCB1—esophageal cancer	8.88e-05	0.000203	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	8.43e-05	0.000192	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	8.28e-05	0.000189	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.91e-05	0.000181	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOS3—esophageal cancer	7.54e-05	0.000172	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	7.19e-05	0.000164	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	7.06e-05	0.000161	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.71e-05	0.000153	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—esophageal cancer	6.23e-05	0.000142	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	6.03e-05	0.000138	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CREBBP—esophageal cancer	5.93e-05	0.000135	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EP300—esophageal cancer	5.74e-05	0.000131	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NOS3—esophageal cancer	5.31e-05	0.000121	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—esophageal cancer	5e-05	0.000114	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGFR—esophageal cancer	4.89e-05	0.000112	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—esophageal cancer	4.86e-05	0.000111	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	4.24e-05	9.69e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—esophageal cancer	4.11e-05	9.37e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—EP300—esophageal cancer	4.04e-05	9.22e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.99e-05	6.82e-05	CbGpPWpGaD
